1
|
Thomas R, Pontius JU, Borst LB, Breen M. Development of a Genome-Wide Oligonucleotide Microarray Platform for Detection of DNA Copy Number Aberrations in Feline Cancers. Vet Sci 2020; 7:vetsci7030088. [PMID: 32645884 PMCID: PMC7560183 DOI: 10.3390/vetsci7030088] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 06/25/2020] [Accepted: 06/30/2020] [Indexed: 12/18/2022] Open
Abstract
The utility of the domestic cat as a model system for biomedical studies was constrained for many years by the absence of a comprehensive feline reference genome sequence assembly. While such a resource now exists, the cat continues to lag behind the domestic dog in terms of integration into the ‘One Health’ era of molecular medicine. Stimulated by the advances being made within the evolving field of comparative cancer genomics, we developed a microarray platform that allows rapid and sensitive detection of DNA copy number aberrations in feline tumors using comparative genomic hybridization analysis. The microarray comprises 110,456 unique oligonucleotide probes anchored at mean intervals of 22.6 kb throughout the feline reference genome sequence assembly, providing ~350-fold higher resolution than was previously possible using this technique. We demonstrate the utility of this resource through genomic profiling of a feline injection-site sarcoma case, revealing a highly disrupted profile of DNA copy number imbalance involving several key cancer-associated genes including KIT,TP53, PTEN, FAS and RB1. These findings were supported by targeted fluorescence in-situ hybridization analysis, which identified major alterations in chromosome structure, including complex intrachromosomal reorganization events typical of those seen in aggressive soft-tissue sarcomas of other species. We then characterized a second mass that was identified at a nearby site in the same patient almost 12 months later. This mass demonstrated a remarkably conserved genomic profile consistent with a recurrence of the original tumor; however the detection of subtle differences reflected evolution of the tumor over time. These findings exemplify the diverse potential of this microarray platform to incorporate domestic cat cancers into comparative and translational research efforts in molecular oncology.
Collapse
Affiliation(s)
- Rachael Thomas
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA;
- Comparative Medicine Institute, North Carolina State University, Raleigh, NC 27606, USA
- Correspondence:
| | - Joan U Pontius
- Laboratory of Genomic Diversity, Basic Research Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick, Frederick, MD 21702, USA;
- Present address: JP Solutions, Ellicott City MD 21042, USA
| | - Luke B Borst
- Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA;
| | - Matthew Breen
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA;
- Comparative Medicine Institute, North Carolina State University, Raleigh, NC 27606, USA
- Center for Human Health and the Environment, North Carolina State University, Raleigh, NC 27607, USA
- Cancer Genetics Program, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, USA
| |
Collapse
|
2
|
Ouahbi H, Amadour L, Elmernissi F, Tahiri L, Harmouch T, Benbrahim Z, Elmrabet F, Arifi S, Oufkigh AA, Mellas N. [Outcome of locally advanced Darier and Ferrand dermatofibrosarcoma: about a case and literature review]. Pan Afr Med J 2019; 32:97. [PMID: 31223387 PMCID: PMC6560964 DOI: 10.11604/pamj.2019.32.97.10293] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Accepted: 11/12/2018] [Indexed: 11/30/2022] Open
Abstract
Le dermatofibrosarcome de Darier et Ferrand (DFS) est une tumeur cutanée rare, caractérisé par son agressivité locale et son important potentiel aux récidives, dont le pronostic dépend essentiellement de la qualité de sa prise en charge. Une réponse complète avec des marges saines d'un DFS qui a été jugé initialement inopérable, après 1 an d'imatinib en situation néoadjuvante est rarement décrite dans littérature. Nous rapportons dans notre article, le cas d'une jeune patiente prise en charge au service d'oncologie médicale de Fès pour une DFS localement avancé présentant une réponse complète, afin d'évaluer la place de l'imatinib et des thérapies ciblées dans le traitement de DFS.
Collapse
Affiliation(s)
- Hajar Ouahbi
- Service d'Oncologie Médicale CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Lamiae Amadour
- Service d'Oncologie Médicale CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Fatimazahra Elmernissi
- Service de Dermatologie CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Layla Tahiri
- Servie d'Anatomopathologie CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Taoufik Harmouch
- Servie d'Anatomopathologie CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Zineb Benbrahim
- Service d'Oncologie Médicale CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Fatimazahra Elmrabet
- Service d'Oncologie Médicale CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Samia Arifi
- Service d'Oncologie Médicale CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Ayat Allah Oufkigh
- Service de Chirurgie Maxillo-faciale et Réparatrice, CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| | - Nawfal Mellas
- Service d'Oncologie Médicale CHU Hassan II, Université Sidi Mohammed Ben Abdellah, Fès, Maroc
| |
Collapse
|
3
|
Bekos C, Grimm C, Brodowicz T, Petru E, Hefler L, Reimer D, Koch H, Reinthaller A, Polterauer S, Polterauer M. Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study. Sci Rep 2017; 7:14474. [PMID: 29101329 PMCID: PMC5670177 DOI: 10.1038/s41598-017-13934-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 10/03/2017] [Indexed: 02/07/2023] Open
Abstract
Fibrinogen has an important pathophysiological role in tumor cell progression and development of metastases in different types of cancer. The present study aimed to evaluate the role of pre-treatment fibrinogen plasma concentrations as a biomarker for tumor biology and prognosis in patients with uterine leiomyosarcoma (ULMS). Clinical data of patients with ULMS were assessed in this multi-center study Pre-therapeutic fibrinogen plasma concentrations were evaluated. We investigated the association between fibrinogen plasma levels and clinico-pathological parameters and performed univariate and multivariable survival analyses. In total, 70 women with ULMS were included into the analysis. Mean (SD) pre-treatment fibrinogen plasma levels were 480.2 (172.3) mg/dL. Patients with advanced tumor stage, increased tumor size and higher histological grading had higher fibrinogen levels (p = 0.02, p = 0.013, and p = 0.029, respectively). In ULMS patients with increased fibrinogen levels 5-year overall survival (OS) rates were 25.0% compared to 52.9% in ULMS patients with normal fibrinogen, respectively. Univariate survival analyses revealed that elevated fibrinogen plasma levels (p = 0.030), advanced tumor stage (p < 0.001) and undifferentiated histology (p = 0.003) showed association with unfavorable OS. In multivariable analysis, histological grade (p = 0.03) and tumor stage (0.02) were independently associated with survival. Elevated fibrinogen plasma levels were associated with aggressive tumor biology and poor prognosis in women with ULMS. Fibrinogen might be useful as a novel biomarker in ULMS.
Collapse
Affiliation(s)
- Christine Bekos
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit - Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Christoph Grimm
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit - Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Thomas Brodowicz
- Clinical Division of Oncology, Department of Medicine 1, Comprehensive Cancer Center - Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Edgar Petru
- Department of Obstetrics and Gynaecology of the Medical University of Graz, Graz, Austria
| | - Lukas Hefler
- Department of Gynaecology, Barmherzige Schwestern Hospital Linz, Linz, Austria
| | - Daniel Reimer
- Department of Obstetrics and Gynaecology of the Medical University of Innsbruck, Tirol, Austria
| | - Horst Koch
- Department of Obstetrics and Gynaecology of the Medical University of Salzburg, Salzburg, Austria
| | - Alexander Reinthaller
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit - Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.,Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna, Austria
| | - Stephan Polterauer
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit - Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. .,Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna, Austria.
| | - Mariella Polterauer
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit - Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| |
Collapse
|
4
|
Schwameis R, Grimm C, Petru E, Natter C, Staudigl C, Lamm W, Koelbl H, Krainer M, Brodowicz T, Reinthaller A, Polterauer S. The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma. PLoS One 2015; 10:e0133838. [PMID: 26248232 PMCID: PMC4527693 DOI: 10.1371/journal.pone.0133838] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Accepted: 06/01/2015] [Indexed: 01/30/2023] Open
Abstract
Objective C-reactive protein (CRP) has previously been shown to serve as a prognostic parameter in women with gynecologic malignancies. Due to the lack of valid prognostic markers for uterine leiomyosarcoma (ULMS) this study set out to investigate the value of pre-treatment CRP serum levels as prognostic parameter. Methods Data of women with ULMS were extracted from databases of three Austrian centres for gynaecologic oncology. Pre-treatment CRP serum levels were measured and correlated with clinico-pathological parameters. Univariate and multivariable survival analyses were performed. Results In total, 53 patients with ULMS were included into the analysis. Mean (SD) CRP serum level was 3.46 mg/dL (3.96). Solely, an association between pre-treatment CRP serum levels and tumor size (p = 0.04) but no other clinic-pathologic parameter such as tumor stage (p = 0.16), or histological grade (p = 0.07), was observed. Univariate and multivariable survival analyses revealed that CRP serum levels (HR 2.7 [1.1–7.2], p = 0.037) and tumor stage (HR 6.1 [1.9–19.5], p = 0.002) were the only independent prognostic factors for overall survival (OS) in patients with ULMS. Patients with high pre-treatment CRP serum levels showed impaired OS compared to women with low levels (5-year-OS rates: 22.6% and 52.3%, p = 0.007). Conclusion High pre-treatment CRP serum levels were independently associated with impaired prognosis in women with ULMS and might serve as a prognostic parameter in these patients.
Collapse
Affiliation(s)
- Richard Schwameis
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Christoph Grimm
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Edgar Petru
- Department of Obstetrics and Gynaecology of the Medical University of Graz, Graz, Austria
| | - Camilla Natter
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Christine Staudigl
- Department of Gynaecology, Barmherzige Schwestern Hospital Linz, Linz, Austria
| | - Wolfgang Lamm
- Clinical Division of Oncology, Department of Medicine 1, Comprehensive Cancer Cente, Medical University Vienna, Vienna, Austria
| | - Heinz Koelbl
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Michael Krainer
- Clinical Division of Oncology, Department of Medicine 1, Comprehensive Cancer Cente, Medical University Vienna, Vienna, Austria
| | - Thomas Brodowicz
- Clinical Division of Oncology, Department of Medicine 1, Comprehensive Cancer Cente, Medical University Vienna, Vienna, Austria
| | - Alexander Reinthaller
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna, Austria
| | - Stephan Polterauer
- Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- * E-mail:
| |
Collapse
|